MedTrace Logo

Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction

NCT00573144 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2014-09-09

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the efficacy of intravenous human beta natriuretic peptide (BNP, Nesiritide) as compared to placebo to prevent adverse post acute myocardial infarction left ventricular remodeling.

Conditions

  • Acute Myocardial Infarction

Interventions

DRUG

Nesiritide

Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.

DRUG

Placebo

Infusion of 72 hours of saline solution (packaged to match active comparator)

Sponsors & Collaborators

Principal Investigators

  • Horng H. Chen, M.D. · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2012-11-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00573144 on ClinicalTrials.gov